Skip to content

Price / book at other companies

Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
Exelixis logo
ExelixisEXEL
5.8×+1.0×
Incyte logo
IncyteINCY
3.3×+0.1×
Roivant Sciences logo
Roivant SciencesROIV
4.4×+2.8×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
AbbVie logo
AbbVieABBV
261×+221×

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Calculated from Summit Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's price / book?
Summit Therapeutics (SMMT) reported price / book of 26.9× in Q1 2026.
How has Summit Therapeutics's price / book changed year-over-year?
Summit Therapeutics's price / book decreased by 34.8% year-over-year, from 41.3× to 26.9×.
What is the long-term trend for Summit Therapeutics's price / book?
Over 5 years (2020 to 2025), Summit Therapeutics's price / book has grown at a -13.8% compound annual growth rate (CAGR), from 41.5× to 19.8×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.